Loading...
Browse all stories on DeepNewz
Visit
Verona Pharma's Ohtuvayre COPD Drug FDA-Approved at $2,950/Month
Jun 27, 2024, 09:27 AM
Verona Pharma, $VRNA, received FDA approval for its COPD drug, Ohtuvayre (ensifentrine), with a wholesale price of $2,950 per month. The drug is seen as a future blockbuster, targeting a significant unmet need in COPD treatment. The company is preparing for market launch with a strong sales and marketing strategy.
View original story
Markets
Yes • 50%
No • 50%
Verona Pharma's financial reports or press releases
Yes • 50%
No • 50%
American Thoracic Society publications or press releases
No • 50%
Yes • 50%
Stock market data from financial news websites or stock exchange listings
31 to 40 states • 25%
More than 40 states • 25%
Less than 25 states • 25%
25 to 30 states • 25%
Insurance company announcements or Verona Pharma press releases
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Market research reports or Verona Pharma's financial disclosures
More than $3 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Less than $1 billion • 25%
Stock market data from financial news websites or stock exchange listings